Literature DB >> 22496155

Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.

Norifumi Sawamukai1, Atsushi Satake, Amanda M Schmidt, Ian T Lamborn, Priti Ojha, Yoshiya Tanaka, Taku Kambayashi.   

Abstract

FoxP3(+) regulatory T cells (Tregs) suppress GVHD while preserving graft-versus-tumor effects, making them an attractive target for GVHD therapy. The donor-derived Treg pool can potentially be derived from the expansion of preexisting natural Tregs (nTregs) or from de novo generation of inducible Tregs (iTregs) from donor Tconvs in the transplantation recipient. Using an MHC-mismatched model of acute GVHD, in the present study we found that the Treg pool was comprised equally of donor-derived nTregs and iTregs. Experiments using various combinations of T cells from wild-type and FoxP3-deficient mice suggested that both preexisting donor nTregs and the generation of iTregs in the recipient mice contribute to protection against GVHD. Surprisingly, CD8(+)FoxP3(+) T cells represented approximately 70% of the iTreg pool. These CD8(+)FoxP3(+) T cells shared phenotypic markers with their CD4(+) counterparts and displayed suppressive activity, suggesting that they were bona fide iTregs. Both CD4(+) and CD8(+) Tregs appeared to be protective against GVHD-induced lethality and required IL-2 and TGFβ receptor expression for their generation. These data illustrate the complex makeup of the donor-derived FoxP3(+) Treg pool in allogeneic recipients and their potential role in protection against GVHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496155      PMCID: PMC3369690          DOI: 10.1182/blood-2011-07-367987

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Molecules and mechanisms of the graft-versus-leukaemia effect.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

Review 2.  Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.

Authors:  Ciriaco A Piccirillo; Ethan M Shevach
Journal:  Semin Immunol       Date:  2004-04       Impact factor: 11.130

3.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse.

Authors:  V L Godfrey; J E Wilkinson; L B Russell
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.

Authors:  Aurélie Trenado; Frédéric Charlotte; Sylvain Fisson; Micael Yagello; David Klatzmann; Benoit L Salomon; José L Cohen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.

Authors:  Stephen C Jones; George F Murphy; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

8.  CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome.

Authors:  Song Guo Zheng; Ju Hua Wang; Michael N Koss; Francisco Quismorio; J Dixon Gray; David Allen Horwitz
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

9.  In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.

Authors:  M Sykes; M L Romick; K A Hoyles; D H Sachs
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.

Authors:  S Srinivas; T Watanabe; C S Lin; C M William; Y Tanabe; T M Jessell; F Costantini
Journal:  BMC Dev Biol       Date:  2001-03-27       Impact factor: 1.978

View more
  22 in total

1.  Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells.

Authors:  Ya Liu; Qin Lan; Ling Lu; Maogen Chen; Zanxian Xia; Jilin Ma; Julie Wang; Huimin Fan; Yi Shen; Bernhard Ryffel; David Brand; Francisco Quismorio; Zhongmin Liu; David A Horwitz; Anping Xu; Song Guo Zheng
Journal:  J Mol Cell Biol       Date:  2013-07-15       Impact factor: 6.216

2.  Control of body temperature and immune function in patients undergoing open surgery for gastric cancer.

Authors:  Li Shao; Nannan Pang; Ping Yan; Fengju Jia; Qi Sun; Wenjuan Ma; Yi Yang
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

3.  The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.

Authors:  Kristin Hollister; Yuxin Chen; Shixia Wang; Hao Wu; Arpita Mondal; Ninah Clegg; Shan Lu; Alexander Dent
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.

Authors:  Nannan Pang; Xianlin Duan; Ming Jiang; Jianhua Qu; Hailong Yuan; Jianli Xu; Haizhou Cao; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

6.  Skin-derived TSLP systemically expands regulatory T cells.

Authors:  Theresa M Leichner; Atsushi Satake; Victor Sanoe Harrison; Yukinori Tanaka; Angela S Archambault; Brian S Kim; Mark C Siracusa; Warren J Leonard; Ali Naji; Gregory F Wu; David Artis; Taku Kambayashi
Journal:  J Autoimmun       Date:  2017-01-23       Impact factor: 7.094

7.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

8.  Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD.

Authors:  Kimberle Agle; Benjamin G Vincent; Clint Piper; Ludovic Belle; Vivian Zhou; Warren Shlomchik; Jonathan S Serody; William R Drobyski
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

9.  Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.

Authors:  Supinya Iamsawat; Anusara Daenthanasanmak; Jessica Heinrichs Voss; Hung Nguyen; David Bastian; Chen Liu; Xue-Zhong Yu
Journal:  J Immunol       Date:  2018-09-21       Impact factor: 5.422

Review 10.  Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions.

Authors:  Joshua F Heiber; Terrence L Geiger
Journal:  Cell Immunol       Date:  2012-10-01       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.